tbuckley/cabot-search huggingface dataset:
Leads from the MMWR. Systemic allergic reactions following immunization with HDCV
Journal: JAMA (1984)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Interpretation of the ECG: before or after mounting? Admissibility as evidence
Authors: David Littman
Journal: JAMA (1971)

<h3>To the Editor.—</h3> The question as it appeared originally inThe Journalwas: "Is an electrocardiogram<i>admissible in evidence in a court of law</i>if it is clipped and mounted before the cardiologist reads the tracing...?" (<b>213</b>:2088, 1970) The concluding portion of the answer was: The mounted excerpt of the ECG may or may not be admissible in evidence, depending upon the issues in the case and the effect of local rules of evidence, but in any event it would seem to me that the weight which it would carry in court could certainly be diminished by a cross-examination which would expose the facts alluded to above. Unlike an x-ray film, a segment of which may or may not be representative of the whole, a single, properly selected beat can be characteristic or typical of the whole lead. Granted that a nonrepresentative single beat could be selected by inadvertence
"Cerebritis"
Authors: HARRY L. ARNOLD
Journal: Annals of Internal Medicine (1974)

Comments and Correction1 October 1974"Cerebritis"HARRY L. ARNOLD JR., M.D., F.A.C.P.HARRY L. ARNOLD JR., M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-81-4-569_2 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: If the term "cerebritis" (Ann Intern Med80:413-414, 1974) is allowable, it should only be on the basis of involvement of the cerebrum to the exclusion of other parts of the encephalon; otherwise, "encephalitis" or "encephalopathy" should be used. Greek roots for diseases, Latin for anatomical names. Surely we wouldn't permit "renitis" or "oculitis"? The exceptions, which aren't many, got in under a grandfather clause that is no longer operative; at least, it shouldn't be invoked without cause, and in the case of lupus erythematosus encephalopathy, the cause seems to be lacking.... This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Straub Clinic & Hospital Honolulu, Hawaii 96813 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 October 1974Volume 81, Issue 4Page: 569-569KeywordsBrainBrain diseasesEncephalitisLupus erythematosus Issue Published: 1 October 1974 PDF DownloadLoading ...
The Capitation Fee
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE FALLIBILITY OF SCIENTIFIC DICTA.
Journal: JAMA (2003)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Dyspeptic Backache
Authors: J. W. Beattie
Journal: Annals of the Rheumatic Diseases (1953)

Not infrequently the back is the site of a pain which at times may be very disabling.This is well known to occur in various spinal conditions involv- ing the skeletal structures.It is also recognized as a feature at times of gynaecological disorders, organic nervous diseases, and states of anxiety and hysteria.Much less appreciated is the fact that backache may be caused by various intra-abdominal lesions.Indeed, as Yaskin and Finkelstein (1944) have emphasized, in some cases vague back pains may be the earliest manifestation of grave abdominal disease.The first description of this association has been attributed by Fagge (1886) to Cruveilhier (1829), who observed, according to Major (1945), that: many patients complain more of a spinal point than of an epigastric point of tenderness.Despite such early recognition, the association of backache with dyspepsia is often overlooked.It is easy to understand such neglect in contrast to more definitive and impressive symptoms such as haema- temesis, vomiting, anorexia, or flatulence.Some reference to the association has been made by Tumen and Yaskin (1946) and by Morrison (1939).The present report seeks to clarify the situation in which dyspeptic backache may arise-as the only or predominant symptom, or as an additional feature in the presence of obvious gastro-intestinal symp- toms.Case Reports Case 1, doctor, aged 41, complained of pain in the back of 10 weeks' duration, which had arisen after an attack of influenza.This pain was situated paraspinally in the region of the T9 and 10, was very severe, and was worse on the right side.It had been present constantly with numbness and tingling both in the back and front segmentally.Exacerbations occurred in which the pain radiated up the back to the scapular region and round to the front in girdle fashion.The patient thought he was suffering from fibrositis or osteo-arthritis of the spine.He also indicated that others had considered his pain to be largely psychogenic.Examination showed that he was very distressed with pain, looking anxious and grey.
IRITIS SENUM.
Authors: ALBERT B. HALE
Journal: JAMA (1900)

Although the study of the iris, in its normal and pathologic conditions is a well-developed field, I have lately had some experiences by which a few new phases in the action of that tissue have been brought out, and the lessons learned therefrom have been so valuable that they deserve special notice, particularly as there seems to be a lack of direct mention of them in text-books which may be considered exhaustive. The outline of a case may well illustrate the point I wish to emphasize. One day last winter I was called to see an old lady of 86, who had caught cold in the eyes the day before. Examination revealed catarrhal conjunctivitis and the patient said that the lids were stuck together in the morning. The left eye seemed to be slightly more involved than the right. There was some annoying pain, but vision was not noticeably affected,
Orofacial dyskinesia. A dental dimension
Authors: H. D. Sutcher
Journal: JAMA (1971)

A movement disorder, orofacial dyskinesia, is characterized by severe, involuntary, dystonic movements of the facial, oral, and cervical musculature. This condition is usually thought to result either from an extrapyramidal disorder or as a complication of phenothiazine therapy. However, certain edentulous dental patients also were observed to have involuntary dystonic movements similar to, but less severe than, those with orofacial dyskinesia. The symptoms of these dental patients responded favorably to prosthetic dental therapy. This suggested that similar dental therapy might be effective in the control of symptoms of orofacial dyskinesia. Four patients with confirmed diagnoses of orofacial dyskinesia wore dentures which had incorrect occlusions (craniomandibular relations). Modifications to correct the denture occlusions effected dramatic symptom reduction in all patients. Disruption of dental proprioception may be an important factor in the genesis of orofacial dyskinesia.
Diethylstilbestrol: recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group
Authors: A. C. Carter
Journal: JAMA (1977)

A total of 523 postmenopausal breast cancer patients with progressive disease were entered in a randomized, double-blind study of four dosages of diethylstilbestrol (DES): 1.5,15,150, or 1,500 mg/day. Higher dosages produced significantly (<i>P</i>&lt;.05) higher regression rates: 21% for the 1,500 mg dosage, 17% for the 150 mg dosage, 15% for the 15 mg dosage, and 10% for 1.5 mg dosage. Durations of regressions were similar regardless of the dosages used to induce them. Although the highest dosage produced the highest regression rate overall, selecting the best dosage or treatment of choice for each type of patient based on menopausal age and on dominant metastatic site would result in more regressions. (<i>JAMA</i>237:2079-2085, 1977)
Gauging the Accuracy of Laboratory Testing From Medicare Data
Authors: Joseph J. Muscato
Journal: JAMA (1993)

<h3>To the Editor.</h3> —Drs Mennemeyer and Winkelman<sup>1</sup>are to be congratulated on attempting to tackle a very difficult problem. However, in their discussion they passed over what might be crucial data they uncovered in their analysis. They point out in the results, but don't discuss, the role of close physician follow-up of these patients. If these patients were receiving warfarin, then 1 PT measurement in a 6-month period is a prescription for disaster. I suspect that most of the patients in this category were not receiving warfarin. However, those who had 5 to 10 PTs in the prior 6 months were almost certainly receiving warfarin, and they had a significantly lower incidence of adverse reactions. Interestingly, those patients tested in physician office laboratories had fewer tests performed (despite a self-referral bias?). Were those patients being tested in physician office laboratories seen less often? One could explore this with office
An open label phase II trial of glufosfamide: A β-D-glucose-linked isophosphoramide mustard given as 1-hour infusion in patients with advanced breast cancer
Authors: G. F. Tidmarsh, I. O. Kudajbergenova, S. N. Navrusov, V. V. Stepula
Journal: Journal of Clinical Oncology (2004)

646 Background: Glufosfamide (Glufo) is a new alkylating agent in which the active metabolite is linked to β-D-glucose to target the glucose transporter system and increase intracellular uptake in tumor cells. The aim of this study was to evaluate the activity and the safety profile of Glufo administered as 2nd line chemotherapy in patients (pts) with metastatic and inoperable breast cancer. Methods: Pts received 5000 mg/m2 of Glufo as a 1-hour infusion every 3 weeks. Anti-tumor activity was assessed according to RECIST criteria and toxicity according to CTC 2.0. The study was approved by the appropriate ethical committees and pts gave written informed consent. Results: Twenty-two pts were included over a 20-month period and all pts received treatment (median age 51 years, WHO performance status 0/1/2: 1/9/12 pts). A total of 42 treatment cycles were administered in 22 pts. Anti-tumor activity: Partial response was observed in 3 of 22 pts (14%) for the ITT population (PP population 3 of 11 pts). Eight of 22 pts (36%) had stable disease. All responders previously failed cyclophoshpamide therapy. Safety profile: Myelotoxicity was generally mild not exceeding CTC grade 2. A decrease of creatinine clearance to CTC grade 3 was observed in 2 pts. Other CTC grade 3 adverse events “likely” or “not assessable “ related to Glufo were vomiting (4 pts), fatigue (1 pt), and neuritis (1 pt). The most frequently observed adverse reaction was nausea, effecting 13 pts, but not exceeding grade 2. No hematuria was observed. Conclusions: Glufo administered as 2nd line chemotherapy revealed anti-tumor activity in breast cancer pts who had previously received an alkylator. Myelotoxicity toxicity was particularly mild. Monitoring of renal function was required. Taken together, our data indicate activity of Glufo in advanced breast cancer and warrant further investigation. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Threshold Pharmaceuticals Threshold Pharmaceuticals Threshold Pharmaceuticals
Officials of the Association 1976-1977
Journal: JAMA (1977)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Arteriovenous fistula for self-treatment of hemophilia
Authors: L. N. Sussman
Journal: JAMA (1974)

THE need for a safe, long-lasting, repetitive, and convenient vascular channel for hemodialysis has been satisfied by the development of the internal arteriovenous fistula by Brescia et al.<sup>1</sup>This technique is easier and less hazardous to patients with bleeding diathesis than that reported by Ries et al.<sup>2</sup>Hemodialysis at home is a possibility, since venipuncture using the fistula can now easily be accomplished by the patient or a family member. Such a fistula has proved to be long lasting and free of complications.<sup>3,4</sup>It can resolve the problem of the patient with difficult veins who needs intravenous therapy in the hospital or at home.<sup>5</sup> <h3>Difficult Venipuncture</h3> The application of the principle of the arteriovenous fistula to the management of hemophilia was suggested when difficulties in venipuncture made hospital care essential for our patient with each minor episode of bleeding. Following the creation of the shunt, the
Glucocorticoid receptor dimerization induces MKP1 to protect against TNF-induced inflammation
Authors: Sofie Vandevyver, Lien Dejager, Tom Van Bogaert, Anna Kleyman, Yusen Liu, Jan Tuckermann, Claude Libert
Journal: Journal of Clinical Investigation (2012)

The Western blots depicted in Figures 4D,5, C and F, and 6A, which used γ-tubulin as a loading control, were derived from gels run separately from those probed with other antibodies.Results were comparable in replicate experiments.
Hematology
Authors: Bruce Furie
Journal: JAMA (1991)

After several decades of fermentation, the explosion of new knowledge in the life sciences is yielding practical benefit to all; the investment of public funds in basic biomedical research over the last two decades has given birth to new understanding of disease processes, new diagnostic methods, and a new generation of therapeutics. Last year was pivotal in hematology with regard to the clinical application of these technologies. Advances in protein biochemistry, molecular biology, and cellular biology have opened new vistas for the study and treatment of many hematologic diseases. The diagnosis and treatment of hemophilia has been a prototype for the study and treatment of other genetic diseases. Although the severity of the hemophilia phenotype has been known to be variable in different families, only now do we appreciate the biological analogue of Murphy's Law: whatever can go wrong will. Hemophilia is a heterogeneous disease characterized by the deficiency of
Observations on Human Tissues and Tumor Proteins
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Pharmacological Studies of the Involvement of Hypothalamic Prostaglandins in the Regulation of Thyrotropin Secretion
Authors: Ken C. Wright, George A. Hedge
Journal: Environmental Health Perspectives (1981)

A case is made for the involvement of pituitary prostaglandins (PGs) in the regulation of thyrotropin (TSH) secretion by citing recent evidence that TSH release in vivo and in vitro is enhanced by treatment with exogenous PGs and is inhibited by drugs (e.g., indomethacin) that block PG synthesis. Pharmacological studies were then performed to test the hypothesis that hypothalamic PGs also affect TSH secretion indirectly via the appropriate hypothalamic hormones that regulate pituitary secretion. The inhibition of thyroidectomy-induced TSH secretion was used as an endpoint in choosing the best of several drugs purported to inhibit PG synthesis. The established effectiveness of indomethacin and aspirin were used for reference in testing the following drugs: naproxen, mefenamic acid, tranylcypromine, and phenelzine. Only naproxen was found to be effective, but since it was no more potent than indomethacin, the latter drug was used for subsequent work. Indomethacin was stereotaxically implanted into several hypothalamic regions known to regulate TSH secretion, and sequential plasma samples were analyzed for TSH by radioimmunoassay. Bilateral implants of indomethacin in the anterior hypothalamic area increased TSH secretion throughout the 72 hr period of study. Sham inplants at this site and indomethacin implants in other nearby sites were ineffective. These findings suggest that endogenous PGs play an inhibitory role in the hypothalamic regulation of pituitary secretion.
Clinicians Advised to Be Aware of New Avian Flu Symptoms
Journal: JAMA (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal